Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
kg azithromycin, kg azithromycin IR · 1 trial · 1 indication
AUC72 = Area under the plasma concentration versus time curve from time zero (pre-dose) to 72 hours.
| Arm | Type | Description |
|---|---|---|
| 1. | ACTIVE_COMPARATOR | 60 mg/kg azithromycin ER (Extended Release)arm |
| 2. | ACTIVE_COMPARATOR | 30 mg/kg azithromycin IR (Immediate Release) arm |
| Name | Type | Description |
|---|---|---|
| 60 mg/kg azithromycin ER | DRUG | subjects taken 60 mg/kg azithromycin ER |
| 30 mg/kg azithromycin IR | DRUG | subjects taken 30 mg/kg azithromycin IR (Immediate Release) |
Inclusion Criteria: * Subjects age 6 months to \< 12 years. * Have clinical signs/symptoms of acute otitis media in at least one ear. * Parent(s)/legal guardian(s) provide written informed consent. Exclusion Criteria: * Clinical significant other disease. * Recent use of investigational drugs, pr...
1 mg, 5 mg, 10 mg is an investigational drug being developed by Pfizer, Inc. (PFE). It is being studied for use in neoplasms, non-Hodgkin lymphoma, meningococcal vaccine, growth disorder, hypercholesterolemia, and non-squamous lung cancer. The drug is currently in Phase 1 clinical development.
1 mg, 5 mg, 10 mg is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for multiple indications including neoplasms and growth disorder.
1 mg, 5 mg, 10 mg is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for conditions such as neoplasms, non-Hodgkin lymphoma, and growth disorder.
1 mg, 5 mg, 10 mg has been studied in clinical trials including NCT00037791 and NCT00039910, which evaluated its safety and efficacy in preventing thrombocytopenia in patients with neoplasms and lymphoma. These trials were Phase 3 and have been completed.
1 mg, 5 mg, 10 mg is associated with the investigational drug PN-152,243, also referred to as PN-196,444. Clinical trials such as NCT00037791 and NCT00039910 studied the safety and efficacy of PN-152,243/PN-196,444 in preventing thrombocytopenia.